LRMR - NASDAQ
Larimar Therapeutics, Inc.
$3.20
-3.0%Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
At a Glance
Live Snapshotlrmr
Total Liabilities
Last Annual Value
67.76M
3-Year CAGR
64%
5-Year CAGR
35%
10-Year CAGR
13%
Larimar Therapeutics, Inc. Competitors Analysis of Total Liabilities
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Larimar Therapeutics, Inc. NASDAQ:LRMR | 67.76M | 68.3% | 36.6% | 21.2% | |
 Alector, Inc. NASDAQ:ALEC | 262.59M | -18.6% | -12.6% | 12.8% | |
 Editas Medicine, Inc. NASDAQ:EDIT | 159.25M | 2.0% | 5.2% | 5.3% | |
 LB Pharmaceuticals Inc Common Stock NASDAQ:LBRX | 11.62M | -47.5% | N/A | N/A | |
 Lyell Immunopharma, Inc. NASDAQ:LYEL | 91.85M | -1.1% | -14.2% | N/A | |
 Tenaya Therapeutics, Inc. NASDAQ:TNYA | 23.66M | -8.7% | -9.1% | N/A | |
 Voyager Therapeutics, Inc. NASDAQ:VYGR | 56.20M | -21.2% | -10.7% | 0.5% | |
 Replimune Group, Inc. NASDAQ:REPL | 135.49M | 14.1% | 25.0% | N/A | |
 Kyverna Therapeutics, Inc. NASDAQ:KYTX | 61.55M | 33.2% | -14.1% | N/A | |
 Korro Bio, Inc. NASDAQ:KRRO | 62.07M | 6.2% | 2.6% | N/A | |
 Lexeo Therapeutics, Inc. Common Stock NASDAQ:LXEO | 22.02M | -5.7% | -35.2% | N/A |
Larimar Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your LRMR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.